GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fangzhou Inc (HKSE:06086) » Definitions » Loans Receivable

Fangzhou (HKSE:06086) Loans Receivable : HK$0 Mil (As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Fangzhou Loans Receivable?

Fangzhou's Loans Receivable for the quarter that ended in Dec. 2023 was HK$0 Mil.


Fangzhou Loans Receivable Historical Data

The historical data trend for Fangzhou's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fangzhou Loans Receivable Chart

Fangzhou Annual Data
Trend Dec21 Dec22 Dec23
Loans Receivable
- - -

Fangzhou Semi-Annual Data
Dec21 Dec22 Dec23
Loans Receivable - - -

Fangzhou Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Fangzhou Loans Receivable Related Terms

Thank you for viewing the detailed overview of Fangzhou's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Fangzhou Business Description

Traded in Other Exchanges
N/A
Address
4th Street, Floor 1-2, Building S, Kehui Jingu, No. 99, Science Avenue, Luogang Science City, Huangpu District, Guangdong Province, Guangzhou, CHN
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
Executives
Crescent China Investment Management Ltd. 2102 Investment manager
Hand David Mckee 2201 Interest of corporation controlled by you
Rojanavanichkul Danai 2201 Interest of corporation controlled by you
Veneto Holdings Ltd. 2201 Interest of corporation controlled by you
Tech-med Cayman Iii Ltd. 2201 Interest of corporation controlled by you
Tech-med Investments (s) Pte. Ltd. 2101 Beneficial owner
Cp Pharmatech Singapore Pte. Ltd. 2101 Beneficial owner
Asia Tech Investments Ltd. 2101 Beneficial owner
Crescent Acso Investment Management Ltd 2201 Interest of corporation controlled by you
Crescent Trident Singapore Pte. Ltd. 2101 Beneficial owner
Xie Fangmin 2201 Interest of corporation controlled by you
Zhou Feng 2201 Interest of corporation controlled by you
Fangrong Management Limited 2101 Beneficial owner
Celaeno Group Limited 2101 Beneficial owner

Fangzhou Headlines

No Headlines